An observational study in Healthy Control Subjects and Schizophrenia Diagnosis, sponsored by Medical University Innsbruck. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Medical University Innsbruck · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Schizophrenia with a site in Austria — 4 open to participants now, 4 under way, none of them phase 3. Schizophrenia · Austria.
Among the 35 studies in Schizophrenia with a site in Austria, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 35th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 35 studies in Schizophrenia with a site in Austria are open now. Recruiting first, the newest first:
Dr. Inge Winter · Sites in Austria, Germany, Italy and 2 more countries
Ages 18–70
Ludwig-Maximilians - University of Munich · Sites in Austria, Germany, Netherlands
Ages 18–65
Medical University of Vienna · Sites in Austria
Ages 18–40 · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is close to the median of 178 across 508 observational studies indexed under Schizophrenia.
Median enrollment 509 across the 33 interventional studies, 265 across the 2 observational. Of the 29 that completed or were terminated, 14 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 35 have an industry lead sponsor. The 10 most frequent:
Medical University Innsbruck is the lead sponsor of 187 studies on the registry; 48 are open to participants now.
Medical University Innsbruck has 2 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Schizophrenia with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to better understand how schizophrenia may affect social thinking, emotion regulation, brain function, and biological processes over time.
Two groups will take part in the study:
Participants in both groups will complete a series of behavioral tasks and questionnaires. These will assess abilities such as understanding other people, processing social information, and regulating emotions. For participants with schizophrenia, we will also assess clinical symptoms and their severity.
The study includes three assessment visits:
At all three visits, participants will complete behavioral tests and questionnaires, and blood and hair samples will be collected. These samples may help researchers investigate biological factors that are related to mental health, stress, and changes over time.
Participants will also undergo an MRI brain scan at the baseline visit and again at the 12-month follow-up.
People with schizophrenia may experience changes in thinking, emotions, social functioning, physical health, and brain function across adulthood. However, we still do not fully understand how these changes develop over time or how they differ from normal aging.
By comparing people with schizophrenia with healthy adults of different ages and following them over time, we can study possible differences in aging trajectories. This means examining whether certain abilities, symptoms, biological markers, or brain characteristics change differently with age in people with schizophrenia.
The study uses an accelerated longitudinal design. Instead of following one group of people for many decades, researchers recruit participants from different age groups and follow them for a shorter period. Combining information across these age groups can help researchers estimate longer-term patterns of change.
Participants with SZ will be recruited through multiple clinical pathways to ensure adequate sample size and representativeness across the adult lifespan. The primary recruitment source is the specialized outpatient clinic for SZ spectrum disorders at the Department of Psychiatry, MUI, which serves a large catchment area and maintains detailed diagnostic records. Additional participants will be recruited through a collaborating psychiatric hospital and office-based psychiatrists and psychosocial service providers in the region, with whom the Dep. of Psychiatry maintains established referral networks. Patients in the SZ group must have a DSM-5 diagnosis of schizophrenia confirmed by their treating psychiatrist. HC participants will be recruited through advertisements in online platforms, social media, and community outreach.
Inclusion criteria (all participants):
age 18-70 years at baseline; normal or corrected-to-normal vision; sufficient hearing; fluency in German; willingness and ability to understand and comply with study procedures. Participants must either be healthy adults without any mental health disorder (HC) or have a confirmed diagnosis of SZ.
Inclusion criteria (SZ only):
clinical stability at assessment, defined as no change in psychopathological symptoms and no modification of pharmacotherapy for at least three months prior to study entry, as confirmed by the treating psychiatrist; full remission is not required.
Exclusion criteria (all participants):
incapacity to consent; current or lifetime history of brain surgery or epilepsy; MRI (unremovable metal parts in the upper body, active implants, claustrophobia); current or past substance abuse disorder (excluding caffeine and nicotine); pregnancy.
Exclusion criteria (HC only):
any current or lifetime Axis I psychiatric disorder; first-degree relative with an Axis I disorder; any neurological disorder or other mental health condition; current or past use of psychotropic medication.
Additional Eligibility Criteria for Cycle-Timed Neuroimaging:
To minimize hormonal confounding of emotion-regulation-related neural measures, menstruating female participants will be scanned in the early follicular phase (cycle days 1-6), requiring regular menstrual cycles (21-35 days) and a negative pregnancy test at relevant visits.
Use of hormonal will be recorded.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group of people with a diagnosis of schizophrenia confirmed by their treating psychiatrist.
Group absent of any Axis-I Diagnosis
Change in Theory of Mind performance
Theory of Mind will be assessed using the EmpaToM task. The outcome will include performance-based indices of cognitive and affective Theory of Mind. Higher scores indicate better ability to infer and understand the mental states of others.
Time frame: Baseline, 12 months, and 24 months
Change in attributional style
Attributional style will be assessed using the Internal, Personal and Situational Attributions Questionnaire-Revised. The outcome will measure tendencies to attribute positive and negative social events to internal, personal-external, or situational-external causes; aswell as monocausal-inference-style.
Time frame: Baseline, 12 months, and 24 months
Change in emotion recognition performance
Emotion recognition will be assessed using the DiagnosIS Emotion Recognition Task. The outcome will measure accuracy in identifying facial emotional expressions. Higher scores indicate better emotion recognition performance.
Time frame: Baseline, 12 months, and 24 months
Change in Emotion Regulation Choice
The Emotion Regulation Choice Task is a behavioral paradigm used to examines whether individuals adapt their choice of emotion regulation strategy according to the intensity of negative emotional stimuli. It will be used to assess the change in the degree to which strategy choice changes as a function of emotional intensity.
Time frame: Baseline, 12 months, 24 months
Change in reflective functioning
Reflective functioning will be assessed using the Reflective Functioning Questionnaire. The outcome will measure certainty and uncertainty about mental states. Scores will be analyzed according to the scoring rules of the instrument.
Time frame: Baseline, 12 months, and 24 months
Change in self reported Emotion Regulation
Self reported emotion regulation will be assessed using the Emotion Regulation Questionnaire (ERQ). The ERQ is a 10-item self-report measure assessing the habitual use of two emotion-regulation strategies: cognitive reappraisal and expressive suppression.
Time frame: Baseline, 12 months, 24 months
Change in global cognitive functioning
Global cognition will be assessed using the Screen for Cognitive Impairment in Psychiatry. The outcome will provide a standardized measure of cognitive functioning across domains including verbal learning, working memory, verbal fluency, and processing speed. Higher scores indicate better cognitive performance.
Time frame: Baseline, 12 months, and 24 months
Change in daily functioning and disability
Daily functioning and disability will be assessed using the World Health Organization Disability Assessment Schedule 2.0. The outcome will measure functioning across cognition, mobility, self-care, interpersonal relationships, life activities, and participation in society. Higher scores indicate greater disability.
Time frame: Baseline, 12 months, and 24 months
Change in brain iron distribution measured by quantitative susceptibility mapping
Brain iron distribution will be assessed using quantitative susceptibility mapping (QSM) derived from multi-echo gradient echo MRI.
Time frame: Baseline and 12 months
Change in R2* relaxometry measures of brain iron-sensitive signal
R2\* values will be derived from multi-echo gradient echo MRI as an iron-sensitive neuroimaging measure.
Time frame: Baseline and 12 months
Change in white matter microstructure
White matter microstructure will be assessed using diffusion-weighted MRI. Outcomes will include fractional anisotropy, mean diffusivity, radial diffusivity, and axial diffusivity.
Time frame: Baseline and 12 months
Change in resting-state functional connectivity
Resting-state functional connectivity will be assessed using resting-state functional MRI.
Time frame: Baseline and 12 months
Change in extracellular vesicle-derived redox markers
Neuronally derived extracellular vesicles will be isolated from plasma samples.
Time frame: Baseline, 12 months, and 24 months
Change in hair proteomic signatures
Hair samples will be analyzed using untargeted proteomic profiling. Outcomes will include proteomic signature related to oxidative stress, antioxidant defense, inflammation, mitochondrial bioenergetics, systemic stress, and biological aging.
Time frame: Baseline, 12 months, and 24 months
Change in hair cortisol concentration
Hair cortisol concentration will be measured from scalp hair samples as an index of cumulative hypothalamic-pituitary-adrenal axis activity over the preceding months. Higher values indicate higher cumulative cortisol exposure.
Time frame: Baseline, 12 months, and 24 months
Change in psychopathological symptom severity
Psychopathological symptoms in participants with schizophrenia will be assessed using the Positive and Negative Syndrome Scale. The outcome will include total and subscale scores for positive symptoms, negative symptoms, and general psychopathology. Higher scores indicate greater symptom severity.
Time frame: Baseline, 12 months, and 24 months
Change in negative symptom severity
Negative symptoms will be assessed using the Brief Negative Symptom Scale. The outcome will measure negative symptom domains including anhedonia, asociality, avolition, blunted affect, and alogia. Higher scores indicate greater negative symptom severity.
Time frame: Baseline, 12 months, and 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2030, 48 months after the start.
Of 114 non-industry observational studies under Schizophrenia, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 114. This study's planned 48 months is close to that.
Counting every sponsor, half of 136 studies reached it within 47 months; a quarter within 27 and three quarters within 102.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University Innsbruck →